AZD3632 + Posaconazole for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Sep 2025: Trial registered, NCT07155226
  2. 9 Jan 2026: Trial started, NCT07155226

The trials

NCT07155226: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

State
Under way
Phase
Phase 1 and Phase 2
People
85 planned
Started
9 Jan 2026
Primary completion
15 Feb 2029
Arms
Module 2: AZD3632 + posaconazole
Results
None posted
  1. 4 Sep 2025: Trial registered
  2. 9 Jan 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.